PL193478B1 - Środek farmaceutyczny i sposób jego wytwarzania - Google Patents

Środek farmaceutyczny i sposób jego wytwarzania

Info

Publication number
PL193478B1
PL193478B1 PL326336A PL32633698A PL193478B1 PL 193478 B1 PL193478 B1 PL 193478B1 PL 326336 A PL326336 A PL 326336A PL 32633698 A PL32633698 A PL 32633698A PL 193478 B1 PL193478 B1 PL 193478B1
Authority
PL
Poland
Prior art keywords
compound
formula
group
mannitol
active ingredient
Prior art date
Application number
PL326336A
Other languages
English (en)
Polish (pl)
Other versions
PL326336A1 (en
Inventor
Klaus Bosslet
Jörg Czech
Manfred Gerken
Rainer Straub
Matthias Blumrich
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PL326336A1 publication Critical patent/PL326336A1/xx
Publication of PL193478B1 publication Critical patent/PL193478B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL326336A 1997-05-15 1998-05-15 Środek farmaceutyczny i sposób jego wytwarzania PL193478B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19720312A DE19720312A1 (de) 1997-05-15 1997-05-15 Zubereitung mit erhöhter in vivo Verträglichkeit

Publications (2)

Publication Number Publication Date
PL326336A1 PL326336A1 (en) 1998-11-23
PL193478B1 true PL193478B1 (pl) 2007-02-28

Family

ID=7829495

Family Applications (1)

Application Number Title Priority Date Filing Date
PL326336A PL193478B1 (pl) 1997-05-15 1998-05-15 Środek farmaceutyczny i sposób jego wytwarzania

Country Status (17)

Country Link
US (1) US6020315A (enExample)
EP (1) EP0879605B1 (enExample)
JP (1) JP4367798B2 (enExample)
KR (1) KR100547923B1 (enExample)
CN (1) CN1188134C (enExample)
AR (1) AR012694A1 (enExample)
AT (1) ATE333899T1 (enExample)
AU (1) AU740694B2 (enExample)
BR (1) BR9801632A (enExample)
CA (1) CA2237450A1 (enExample)
CZ (1) CZ149398A3 (enExample)
DE (2) DE19720312A1 (enExample)
HU (1) HUP9801087A3 (enExample)
ID (1) ID20283A (enExample)
PL (1) PL193478B1 (enExample)
RU (1) RU2234322C2 (enExample)
TR (1) TR199800848A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
EP0903348B2 (de) 1995-11-17 2008-08-27 Gesellschaft für Biotechnologische Forschung mbH (GBF) Epothilon-Derivate und deren Herstellung
EP0941227B2 (de) 1996-11-18 2009-10-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
DE69734362T2 (de) 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ID22891A (id) * 1997-08-26 1999-12-16 Hoechst Marion Roussel Inc Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
KR100685336B1 (ko) 1999-02-22 2007-02-23 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) Ｃ-21 변형 에포틸론
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
WO2000066612A1 (en) 1999-05-04 2000-11-09 Strakan Limited Androgen glycosides and androgenic activity thereof
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
GB2355007A (en) * 1999-10-08 2001-04-11 Michael Francis Holick Tamoxifen analogue glycosides and use thereof
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
JP2004511510A (ja) * 2000-10-16 2004-04-15 ネオファーム、インコーポレイティッド ミトキサントロンのリポソーム製剤
HU229349B1 (en) 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
JP2004522771A (ja) 2001-02-20 2004-07-29 ブリストル−マイヤーズ　スクイブ　カンパニー 治療抵抗性腫瘍の処置用エポチロン誘導体
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
JP2004532888A (ja) 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
EP1423126B1 (en) * 2001-08-14 2007-08-29 Valderm APS Treatment of hyperproliferative conditions of body surfaces
US20030194421A1 (en) * 2001-12-28 2003-10-16 Angiotech Pharmaceuticals, Inc. Treatment of uveitis
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RU2368661C2 (ru) 2002-09-23 2009-09-27 Бристол-Маерс Сквибб Компани Способы получения, выделения и очистки эпотилона b и рентгеноструктурные кристаллические структуры эпотилона в
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) * 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
EP2114157B1 (en) * 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US20090118031A1 (en) * 2007-11-01 2009-05-07 Qualizza Gregory K Shaft Structure with Configurable Bending Profile
WO2013026454A1 (en) * 2011-08-22 2013-02-28 Valderm Aps Treatment of clinical conditions with anthracyclines
GB201414806D0 (en) * 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
EP0751144B1 (en) * 1995-06-27 2004-10-06 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy
SI0795334T1 (sl) * 1996-03-12 2006-06-30 Sanofi Aventis Deutschland Predzdravila za zdravljenje tumorjev in vnetnih bolezni

Also Published As

Publication number Publication date
JP4367798B2 (ja) 2009-11-18
AU740694B2 (en) 2001-11-15
RU2234322C2 (ru) 2004-08-20
CA2237450A1 (en) 1998-11-15
TR199800848A3 (tr) 1998-12-21
CN1188134C (zh) 2005-02-09
EP0879605A2 (de) 1998-11-25
HUP9801087A3 (en) 1999-05-28
JPH1129497A (ja) 1999-02-02
HU9801087D0 (en) 1998-07-28
CZ149398A3 (cs) 1998-12-16
ID20283A (id) 1998-11-19
AU6600598A (en) 1998-11-19
DE59813653D1 (de) 2006-09-07
PL326336A1 (en) 1998-11-23
DE19720312A1 (de) 1998-11-19
BR9801632A (pt) 1999-06-29
HUP9801087A2 (hu) 1998-12-28
EP0879605B1 (de) 2006-07-26
EP0879605A3 (de) 1998-12-02
AR012694A1 (es) 2000-11-08
KR19980087239A (ko) 1998-12-05
US6020315A (en) 2000-02-01
ATE333899T1 (de) 2006-08-15
CN1199613A (zh) 1998-11-25
KR100547923B1 (ko) 2006-04-12
TR199800848A2 (xx) 1998-12-21

Similar Documents

Publication Publication Date Title
PL193478B1 (pl) Środek farmaceutyczny i sposób jego wytwarzania
EP1165069B1 (en) Antitumour synergistic composition
EP0004467B1 (en) Bis-anthracyclines, methods of making and using them and liposome compositions for administering them
CN1980637B (zh) 用于药物输送的脂质体
US8299033B2 (en) Iodo-hexose compounds useful to treat cancer
EP0181154A2 (en) Galactose-C-6 nitrogen mustard compounds and their uses
US20080069899A1 (en) Pharmaceutical Compositions Comprising Beta-Carboline Derivatives and Use Thereof for the Treatment of Cancer
CN116077631A (zh) 涉及粘液素的疾病治疗
TW202432119A (zh) 作為sting促效劑之雜環化合物
Vecchi et al. Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate
US20080027023A1 (en) Antiproliferative Compositions Comprising Aryl Substituted Xylopyranoside Derivatives
Parker et al. N-Trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies
DE69121551T2 (de) Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
JP4780834B2 (ja) 新規なプテリン抗新生物薬
US20100227831A1 (en) Compositions and methods for cancer treatment
RU2345086C2 (ru) Способ получения цис-диаммонийдихлордигидроксоплатины (iv) и ее применение
JP2511709B2 (ja) キサントシリンｘモノメチルエ―テル誘導体及びそれを含有する抗腫瘍剤
EP3470403B1 (en) Taxoid compound and preparation method and use thereof
EP1169035B1 (en) Anti-tumor synergetic composition
EP1200099B1 (en) Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds
JP4509574B2 (ja) 癌化学治療改善剤
US20040038904A1 (en) Method of treating multiple sclerosis
JPH0667834B2 (ja) 抗腫瘍剤
RU2279277C2 (ru) Лечение разделенными дозами агентов с сосудоразрушающей активностью
JPH0120128B2 (enExample)